IDEXX Laboratories, Inc.

Equities

IDXX

US45168D1046

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-06-20 pm EDT			5-day change	1st Jan Change
523.92 ^USD	+0.78%		+0.23%	+26.72%

Jun. 20	IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2025, May-28-2025 10:55 AM
Jun. 19	IDEXX Laboratories, Inc., Q1 2025 Earnings Call, May 01, 2025

Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.

Published on 05/01/2025 at 12:11, updated on 05/01/2025 at 16:11

From January 1, 2025 to March 31, 2025, the company has repurchased 930,800 shares, representing 1.14% for $409 million. With this, the company has completed the repurchase of 72,797,254 shares, representing 60.51% for $7,128.24 million under the buyback announced on August 13, 1999.

Latest news about IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc. Presents at Stifel Jaws & Paws Conference 2025, May-28-2025 10:55 AM	Jun. 20
IDEXX Laboratories, Inc., Q1 2025 Earnings Call, May 01, 2025	Jun. 19
Leerink Partners Adjusts IDEXX Laboratories Price Target to $580 From $515	Jun. 11	MT
IDEXX Laboratories, Inc. Announces the Launch of the Catalyst®? Cortisol Test	Jun. 05	CI
Idexx Laboratories - Launches Catalyst Cortisol Test For Diagnosing Addison's Disease And Managing Cushing's Syndrome In Dogs	Jun. 05	RE
Stifel Adjusts Price Target on IDEXX Laboratories to $510 From $460, Maintains Hold Rating	May. 19	MT
BNP Paribas Exane Adjusts Price Target on IDEXX Laboratories to $577 From $566, Maintains Outperform Rating	May. 12	MT
BTIG Raises Price Target on IDEXX Laboratories to $545 From $530, Maintains Buy Rating	May. 05	MT
Morgan Stanley Adjusts Price Target on IDEXX Laboratories to $558 From $548, Maintains Overweight Rating	May. 05	MT
Leerink Partners Adjusts IDEXX Laboratories Price Target to $515 From $500	May. 02	MT
Tranche Update on IDEXX Laboratories, Inc.'s Equity Buyback Plan announced on August 13, 1999.	May. 01	CI
IDEXX Laboratories raises annual profit view on strong demand for its pet diagnostics	May. 01	RE
IDEXX Laboratories Q1 Earnings, Revenue Increase; 2025 Outlook Raised	May. 01	MT
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 Revenue $998.4M, vs. FactSet Est of $997.1M	May. 01	MT
Earnings Flash (IDXX) IDEXX Laboratories Posts Q1 EPS $2.96, vs. FactSet Est of $2.85	May. 01	MT
(IDXX) Idexx Laboratories Sees Fiscal Year 2025 EPS Range $11.93 - $12.43	May. 01	MT
Earnings Flash (IDXX) Idexx Laboratories Posts Q1 Revenue $998.4M, vs. FactSet Est of $997.1M	May. 01	MT
IDEXX Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	May. 01	CI
Idexx Laboratories, Inc. Updates Financial Guidance for 2025	May. 01	CI
BofA Trims Price Target on IDEXX Laboratories to $475 From $535, Maintains Neutral Rating	Apr. 21	MT
Leerink Partners Adjusts Price Target on IDEXX Laboratories to $500 From $525, Maintains Outperform Rating	Apr. 21	MT
Morgan Stanley Adjusts IDEXX Laboratories' Price Target to $548 From $559, Keeps Overweight Rating	Apr. 15	MT
Stifel Adjusts IDEXX Laboratories' PT to $420 From $450, Keeps Hold Rating	Apr. 14	MT
ImmuCell Corporation Appoints Timothy C. Fiori as Chief Financial Officer	Apr. 07	CI
IDEXX Laboratories, Inc. Presents at Raymond James & Associates? 46th Annual Institutional Investors Conference 2025, Mar-03-2025 11:35 AM	Mar. 03

Chart IDEXX Laboratories, Inc.

Duration

Period

IDXX: Dynamic Chart

Company Profile

IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows: - veterinary diagnoses for pets (91.8%); - water quality analysis (4.7%); - veterinary diagnoses for livestock and poultry (3.1%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products; - other (0.4%). Net sales by source of income break down between product sales (57.7%) and services (42.3%). Net sales are distributed geographically as follows: the United States (65%), Canada (3.9%), Americas (2.1%), Germany (4.5%), the United Kingdom (3.5%), France (2.9%), Spain (1.6%), Italy (1.5%), Switzerland (0.9%), Netherlands (0.9%), Europe/Middle East/Africa (5.1%), Australia (2.5%), Japan (1.9%), China (0.9%) and Asia/Pacific (2.8%).

Employees

11,000

Sector

Medical Equipment, Supplies & Distribution

Calendar

Aug. 04 - Q2 2025 Earnings Release

More about the company